Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System (VIVID)

• ClinicalTrials.gov Identifier: NCT04580160
• Recruitment Status: Recruiting
• First Posted: October 8, 2020
• Last Update Posted: January 22, 2021
• Sponsor: Vesper Medical, Inc.
• Information provided by (Responsible Party): Vesper Medical, Inc.

Study Description

Brief Summary:

This is a prospective, multi-center, single-arm, non-blinded clinical trial designed to investigate the safety and efficacy of the Vesper DUO Venous Stent System as compared to a pre-defined performance goal (PG) established from published, peer reviewed scientific literature related to stenting of iliofemoral venous outflow obstructions.

Condition or disease	Intervention/treatment	Phase
May-Thurner Syndrome; Deep Vein Thrombosis; Chronic Venous Insufficiency	Device: Duo Venous Stent System	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 160 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
• Actual Study Start Date: November 30, 2020
• Estimated Primary Completion Date: December 2022
• Estimated Study Completion Date: December 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: Duo Venous Stent System Implantation	Device: Duo Venous Stent System; Subjects with nonmalignant iliofemoral venous outflow obstruction presenting with nonthrombotic (NT), acute thrombotic (AT) or chronic postthrombotic (CPT) disease pathogenesis will be selected for study participation.

Outcome Measures

Primary Outcome Measures :

1. Safety - Freedom from major adverse events (MAEs) at 30 days [ Time Frame: 30 days ]

   Freedom from major adverse events (MAEs) at 30 days post index procedure, as adjudicated by the Clinical Events Committee (CEC) or Core Laboratory, including:

   • Device or procedure-related death
   • Device or procedure-related bleed at the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention or blood transfusion of ≥2 units
   • Device or procedure-related venous injury occurring in the target vessel and/or the target lesion or at the access site requiring surgical or endovascular intervention
   • Major amputation of the target limb
   • Clinically significant pulmonary embolism (PE), confirmed by CT angiography
   • Stent embolization outside of the target vessel
   • Presence of new thrombus within the stented segment
2. Efficacy - Primary patency of stented segment at 12 months [ Time Frame: 12 months ]

   Primary patency of stented segment at 12 months defined as freedom from:

   • Duplex Ultrasound (DUS) core laboratory adjudicated stenosis or occlusion >50% within the stented segment. If DUS shows >50% stenosis or occlusion, confirmation by diagnostic intravascular ultrasound (IVUS) is required.
   • CEC adjudicated clinically driven target lesion reintervention (CD-TLR) defined as endovascular or surgical procedure for new, recurrent, or worsening symptoms and core lab adjudicated >50% stenosis or occlusion within the stented segment confirmed by diagnostic IVUS

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Males or non-pregnant females ≥18 years of age at the time of consent
2. Subject is able and willing to provide written informed consent prior to receiving any non-standard of care, protocol specific procedures
3. Female subjects of childbearing potential must have a negative pregnancy test within 7 days prior to treatment and must use some form of contraception (abstinence is acceptable) throughout the time of clinical trial exit
4. Willing and capable of complying with all required follow-up visits
5. Estimated life expectancy ≥1 year
6. Subject is ambulatory (use of assistive walking device such as a cane or walker is acceptable)
7. Body mass index (BMI) <40

8. Clinically significant symptomatic venous outflow obstruction in one iliofemoral venous segment (one limb) per subject, is indicated for venoplasty and stenting, and meets at least one of the following clinical indicators:

   1. CEAP score ≥3
   2. VCSS pain score ≥2
   3. Suspected deep vein thrombosis (DVT) with symptoms occurring prior to receiving a DUO Stent
9. Subject is willing and able to comply with PI recommendation for compression therapy, if required
10. Presence of unilateral, non-malignant venous obstruction of the common femoral vein (CFV), external iliac vein (EIV), common iliac vein (CIV), or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter and confirmed by venographic or IVUS imaging. The cranial point of the obstruction may extend to the iliac vein confluence of the inferior vena cava (IVC) and the caudal point may be 2mm above either the inflow of the deep femoral (or profunda) or the lesser trochanter, whichever is most cranial
11. Obstructive lesion(s) able to be treated with continuous stent coverage
12. Adequate inflow to the target lesion(s) involving at least a patent femoral or deep femoral vein and a landing zone in the CFV free from significant disease requiring treatment
13. Reference vessel diameter is of adequate size to accommodate the appropriate size stent as measured by IVUS
14. All vessels from insertion site through target vessel can accommodate a 9F or 10F sheath, depending on the stent size used
15. Ability to cross interventional devices through target lesion(s) with successful pre-dilation
16. In DVT subjects, successful treatment of acute thrombus must have occurred prior to receiving any DUO Stents for an underlying obstructive lesion. Successful treatment of acute thrombus is defined as reestablishment of antegrade flow with ≤30% residual thrombus (confirmed by venogram or IVUS) and freedom from bleeding and symptomatic pulmonary embolism (confirmed by imaging). After successful treatment of thrombus is confirmed, eligible obstructive lesion(s) can be treated with a DUO Stent during the same procedure.
17. All subjects must undergo a SARS-CoV-2 test (antibody testing not allowed) and have a negative test result within 8 days of the index procedure. If a SARS-CoV-2 test is unavailable due to institution policy, a test shortage, or if there is a delay in test results, the subject must complete the COVID-19 questionnaire and must have answered NO to all questions to be eligible for enrollment
18. A measured temperature less than 99.5°F (37.5°C) on the day of the index procedure and no history of fever or feeling feverish within 14 days of the index procedure
19. No prior history, within 60 days of the index procedure, of a SARS-CoV-2 positive test, SARS-CoV-2 positive antibody test, or COVID-19 symptoms

Exclusion Criteria:

1. Target limb symptoms caused by peripheral arterial disease
2. Presence of unresolved significant PE prior to use of the DUO Venous Stent System confirmed by chest CT. If subject has documented history of significant pulmonary embolism within the last 6 months, a chest CT is required to confirm significant pulmonary embolism is not currently present.
3. Presence of IVC obstruction or target venous obstruction that extends into the IVC
4. Presence of acute DVT located outside target limb
5. Contralateral venous occlusive disease of the CFV, EIV, and/or CIV, with planned treatment ≤390 days after the index procedure
6. Uncontrolled or active coagulopathy or known, uncorrectable bleeding diathesis
7. Coagulopathy causing INR >2 which is not amenable to medical treatment
8. Platelet count <50,000 cells/mm3 or >1,000,000 cells/mm3 and/or White blood cell (WBC) <3,000 cells/mm3 or >12,500 cells/mm3
9. Uncorrected hemoglobin of ≤9 g/dL
10. Subject is on dialysis or has an estimated glomerular filtration rate (eGFR) <30 mL/min. In subjects with diabetes mellitus, eGFR <45 mL/min.
11. History of Heparin Induced Thrombocytopenia
12. Presence of known aggressive clotting disorders such as Lupus Anticoagulant Disorder, Antiphospholipid antibody syndrome, homozygous gene Factor V Leiden or Prothrombin gene abnormalities, Protein C and S deficiency or Antithrombin deficiency
13. Known hypersensitivity or contraindication to antiplatelet therapy or anticoagulation, nickel, or titanium
14. Contrast agent allergy that cannot be managed adequately with pre-medication
15. Intended concurrent adjuvant procedure (except for venoplasty) such as creation of temporary arteriovenous fistula, femoral endovenectomy or saphenous vein ablation and/or saphenous vein stripping during the index procedure
16. Subjects who have had any prior surgical or endovascular procedures to the target vessel. Note that subjects who have had successful catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 90 days prior to the index procedure may be included
17. Planned surgical or interventional procedures of the target limb (except thrombolysis and/or thrombectomy in preparation for the procedure or vena cava filter placement prior to stent implantation in subjects at high risk for pulmonary embolism) within 30 days prior to or 30 days after the index procedure
18. Planned surgical or interventional procedures for other medical conditions (i.e., not associated with the target limb) 30 days prior to or 30 days after the index procedure
19. Previous venous stenting of the target limb, the IVC, or contralateral limb if stents extend into the IVC
20. Iliofemoral venous segment unsuitable for treatment with available sizes of DUO Stent implants
21. Lesions with intended treatment lengths extending into the IVC
22. No safe landing zone at or above the profunda femoral confluence
23. Participating in another investigational study in which the subject has not completed the primary endpoint(s)
24. Has other comorbidities that, in the opinion of the Investigator, would preclude them from receiving this treatment and/or participating in study-required follow-up assessments

Contacts and Locations

Contacts

Contact: Joseph C Griffin; 14848926340; jgriffin@vespermedical.com

Locations

United States, Connecticut

The Vascular Experts; Recruiting

Darien, Connecticut, United States, 06820

Contact: Maria Myslinski 201-956-6834

Principal Investigator: Paul Gagne, MD

United States, Michigan

Michigan Outpatient Vascular Institute; Recruiting

Dearborn, Michigan, United States, 48126

Contact: Jessica Shuck 313-724-9000

Principal Investigator: Elias Kassab, MD

United States, Texas

North Dallas Research Associates; Recruiting

McKinney, Texas, United States, 75069

Contact: Samina Ahsanullah 972-562-2345

Principal Investigator: Muhammad A Khan, MD

Hurricane Cardiology Research; Recruiting

New Braunfels, Texas, United States, 78130

Contact: Kristen Hlozek 857-334-0851

Principal Investigator: Jason Yoho, MD

Sponsors and Collaborators

Vesper Medical, Inc.

More Information

• Responsible Party: Vesper Medical, Inc.
• ClinicalTrials.gov Identifier: NCT04580160
• Other Study ID Numbers: V-CA-0001
• First Posted: October 8, 2020
• Last Update Posted: January 22, 2021
• Last Verified: January 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Device Product Not Approved or Cleared by U.S. FDA: Yes

Additional relevant MeSH terms:

Thrombosis; Venous Thrombosis; Venous Insufficiency; May-Thurner Syndrome; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases; Vascular Malformations; Cardiovascular Abnormalities; Peripheral Vascular Diseases; Congenital Abnormalities